1.06 USD
-0.27 (-20.3%)
1.07 USD
+0.01 (+0.94%)
MNDR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 100 industry peers in the Health Care Providers & Services industry. MNDR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MNDR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year MNDR has reported negative net income.
MNDR had a negative operating cash flow in the past year.
In the past 5 years MNDR reported 4 times negative net income.
In the past 5 years MNDR reported 4 times negative operating cash flow.
1.2 Ratios
MNDR has a worse Return On Assets (-113.31%) than 96.00% of its industry peers.
MNDR's Return On Equity of -192.59% is on the low side compared to the rest of the industry. MNDR is outperformed by 79.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.31% | ||
| ROE | -192.59% | ||
| ROIC | N/A |
ROA(3y)-121.89%
ROA(5y)-86.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 16.06%, MNDR is not doing good in the industry: 64.00% of the companies in the same industry are doing better.
MNDR's Gross Margin has declined in the last couple of years.
MNDR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 16.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.44%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MNDR has been reduced compared to 1 year ago.
There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MNDR has an Altman-Z score of -9.44. This is a bad value and indicates that MNDR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.44, MNDR is doing worse than 93.00% of the companies in the same industry.
There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.44 |
ROIC/WACCN/A
WACC8.83%
2.3 Liquidity
A Current Ratio of 1.06 indicates that MNDR should not have too much problems paying its short term obligations.
With a Current ratio value of 1.06, MNDR is not doing good in the industry: 67.00% of the companies in the same industry are doing better.
MNDR has a Quick Ratio of 1.06. This is a bad value and indicates that MNDR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.99, MNDR is doing worse than 67.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
MNDR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -303.19%.
The Revenue for MNDR has decreased by -42.16% in the past year. This is quite bad
The Revenue has been growing slightly by 3.04% on average over the past years.
EPS 1Y (TTM)-303.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325.52%
Revenue 1Y (TTM)-42.16%
Revenue growth 3Y3.04%
Revenue growth 5YN/A
Sales Q2Q%-45.26%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y150%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year76.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MNDR. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 51.96 indicates a quite expensive valuation of MNDR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MNDR is on the same level as its industry peers.
MNDR's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.78.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 51.96 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MNDR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for MNDR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.06
-0.27 (-20.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.39%
Inst Owner Change-97.19%
Ins Owners12.22%
Ins Owner ChangeN/A
Market Cap1.94M
Revenue(TTM)11.92M
Net Income(TTM)-5.04M
Analysts82.86
Price TargetN/A
Short Float %49.04%
Short Ratio0.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 51.96 | ||
| P/S | 0.16 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.74 | ||
| P/tB | 7.58 | ||
| EV/EBITDA | N/A |
EPS(TTM)-19.48
EYN/A
EPS(NY)0.02
Fwd EY1.92%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS6.52
BVpS1.43
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.31% | ||
| ROE | -192.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 16.06% | ||
| FCFM | N/A |
ROA(3y)-121.89%
ROA(5y)-86.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.44%
GM growth 5YN/A
F-Score4
Asset Turnover2.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1416.51% | ||
| Cap/Sales | 20.44% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | -9.44 |
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)567.57%
Cap/Depr(5y)346.48%
Cap/Sales(3y)11.73%
Cap/Sales(5y)7.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-303.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-325.52%
EPS Next Y150%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.16%
Revenue growth 3Y3.04%
Revenue growth 5YN/A
Sales Q2Q%-45.26%
Revenue Next Year76.44%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y69.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.12%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.94%
OCF growth 3YN/A
OCF growth 5YN/A
MOBILE-HEALTH NETWORK SOLUTI / MNDR FAQ
What is the ChartMill fundamental rating of MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MNDR.
What is the valuation status of MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?
ChartMill assigns a valuation rating of 1 / 10 to MOBILE-HEALTH NETWORK SOLUTI (MNDR). This can be considered as Overvalued.
How profitable is MOBILE-HEALTH NETWORK SOLUTI (MNDR) stock?
MOBILE-HEALTH NETWORK SOLUTI (MNDR) has a profitability rating of 0 / 10.
Can you provide the financial health for MNDR stock?
The financial health rating of MOBILE-HEALTH NETWORK SOLUTI (MNDR) is 5 / 10.